Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
sabato, ottobre 03
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Foghorn Therapeutics Inc
FHTX
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$2.02
-0.90
-30.82%
Ult. Agg.: Oct 2, 7:51 PM
$1.99
-0.93
-31.68%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
PRO
Perché si muove?:
Foghorn Therapeutics shares are trading lower after multiple analyst firms ...
Foghorn Therapeutics Financials
Foghorn Therapeutics (FHTX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Foghorn Therapeutics Q2 EPS $(0.10) Beats $(0.23) Estimate, Sales $16.072M Beat $5.995M Estimate
Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.23) by 54.55 percent. This is a 64.29 percent increase over losses of $(0.28) per share
Benzinga Newsdesk
PRO
Foghorn Therapeutics Q1 EPS $(0.29), Inline, Sales $3.267M Miss $7.438M Estimate
Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.29) per share which met the analyst consensus estimate. This is a 3.33 percent increase over losses of $(0.30) per share from the same period last year.
Benzinga Newsdesk
PRO
Foghorn Therapeutics Q4 EPS $(0.34) Misses $(0.27) Estimate, Sales $9.247M Miss $9.500M Estimate
.
Benzinga Newsdesk
PRO
Foghorn Therapeutics Q3 EPS $(0.25) Beats $(0.30) Estimate, Sales $8.153M Beat $6.197M Estimate
Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.30) by 17.76 percent. This is a 19.35 percent increase over losses of $(0.31) per share
Benzinga Newsdesk
PRO
Foghorn Therapeutics Q2 EPS $(0.28) Beats $(0.33) Estimate, Sales $7.557M Beat $6.498M Estimate
Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.33) by 13.85 percent. This is a 37.78 percent increase over losses of $(0.45) per share
Benzinga Newsdesk
PRO
Foghorn Therapeutics Q1 EPS $(0.30) Beats $(0.31) Estimate, Sales $5.95M Beat $5.82M Estimate
Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.31) by 3.23 percent. This is a 49.15 percent increase over losses of $(0.59) per share
Benzinga Newsdesk
